Oxaliplatin/Capecitabine combination (Xelox) with or without targeted therapies in advanced colorectal cancer (ACRC) and pharmacokinetic analysis

被引：0
|
作者：
Gil-Delgado, M. [1 ,2 ,3 ,4 ]
Bastian, G. [1 ,2 ,3 ,4 ]
Spano, J. [1 ,2 ,3 ,4 ]
Paule, B. [1 ,2 ,3 ,4 ]
Des-Guetz, G. [1 ,2 ,3 ,4 ]
Bardier-Dupas, A. [1 ,2 ,3 ,4 ]
Khayat, D. [1 ,2 ,3 ,4 ]
机构：
[1] Med Oncol Serv, Paris, France
[2] Hop La Pitie Salpetriere, Paris, France
[3] Hop Paul Brousse, Villejuif, France
[4] Hop Avicenne, F-93009 Bobigny, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15068
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Final results of pharmacokinetic study of oxaliplatin and capecitabine combination for advanced colorectal cancer
    William-Faltaos, Sara
    Rouillard, Dany
    Lechat, Philippe
    Bastian, Gerard
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 (02) : 165 - 172
  • [2] Pharmacokinetic study of oxaliplatin (lohp) and capecitabine combination in advanced colorectal cancer.
    Gil-Delgado, M
    Bastian, G
    Paule, B
    Urien, S
    Spano, JP
    Deguetz, G
    Chouania, K
    Saintini, P
    Breau, JL
    Khayat, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 154S - 154S
  • [3] Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer
    Mohamad Farid
    Balram Chowbay
    Xiangai Chen
    Sze Huey Tan
    Saminathan Ramasamy
    Wen Hsin Koo
    Han Chong Toh
    Su Pin Choo
    Simon Yew Kuang Ong
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 141 - 150
  • [4] Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer
    Farid, Mohamad
    Chowbay, Balram
    Chen, Xiangai
    Tan, Sze Huey
    Ramasamy, Saminathan
    Koo, Wen Hsin
    Toh, Han Chong
    Choo, Su Pin
    Ong, Simon Yew Kuang
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (01) : 141 - 150
  • [5] Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer
    Park, Yeon Hee
    Lee, Jae-Lyun
    Ryoo, Baek-Yeol
    Ryu, Min-Hee
    Yang, Sung Hyun
    Kim, Bong Seog
    Shin, Dong Bok
    Chang, Heung Moon
    Kim, Tae Won
    Yuh, Young Jin
    Kang, Yoon-Koo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (04) : 623 - 629
  • [6] Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer
    Yeon Hee Park
    Jae-Lyun Lee
    Baek-Yeol Ryoo
    Min-Hee Ryu
    Sung Hyun Yang
    Bong Seog Kim
    Dong Bok Shin
    Heung Moon Chang
    Tae Won Kim
    Young Jin Yuh
    Yoon-Koo Kang
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 623 - 629
  • [7] BI-WEEKLY ADMINISTRATION OF CAPECITABINE plus OXALIPLATIN (XELOX-2) IN FIRST LINE TREATMENT OF ADVANCED COLORECTAL CANCER (ACRC): PRELIMINARY RESULTS
    Di Bisceglie, M.
    Di Maggio, G.
    Giuliani, F.
    Lorusso, V.
    Cinieri, S.
    Colucci, G.
    Maiello, E.
    EJC SUPPLEMENTS, 2008, 6 (14): : 120 - 120
  • [8] Phase II study of the combination of bevacizumab (Rhumab VEGF) and oxaliplatin plus capecitabine (Xelox) in patients with advanced colorectal cancer
    Sarmiento, R.
    Frustaci, S.
    Bonadonna, A.
    Ravaioli, A.
    Oliviero, G.
    Mattioli, R.
    Tarnburrano, T.
    Gebbia, V
    Agueli, R.
    Torino, F.
    Lo Noce, V
    Veri, A.
    Gasparini, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 85 - 86
  • [9] PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB (RHUMAB VEGF) AND OXALIPLATIN PLUS CAPECITABINE (XELOX) IN PATIENTS WITH ADVANCED COLORECTAL CANCER
    Sarmiento, R.
    Frustaci, S.
    Torino, F.
    Ravaioli, A.
    Mattioli, R.
    Gebbia, V.
    Veri, A.
    Gasparini, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 144 - 144
  • [10] Two doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer
    Moreno-Solorzano, Isabel
    Ibeas-Rollan, Rafael
    Monzo-Planella, Mariano
    Moreno-Solorzano, Jose
    Martinez-Rodenas, Francisco
    Pou-Sanchis, Edmon
    Hernandez-Borlan, Raquel
    Navarro-Vigo, Marta
    Ortigosa-Rodriguez, Silvia
    Gel-Moreno, Bernat
    CLINICAL COLORECTAL CANCER, 2007, 6 (09) : 634 - 640
12345